Advanced Therapies

Sickle cells
#Beam Therapeutics #Cell therapy #Phase II trial #Sickle cell disorder (SCD)

Trial results support US biologics license application for risto-cel

Beam Therapeutics has shared positive topline results from the BEACON Phase I/II study evaluating ristoglogene autogetemcel (risto-cel) in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs).   Risto-cel is an investigational one-time, autologous cell therapy with a potentially differentiated profile for the treatment of SCD. Read More

#News #Trending News

CAR-T therapy
#Allogene Therapeutics #Autoimmune disease #CAR-T #Cell therapy #Phase I trial

First clinical data for allogeneic CAR-T in autoimmune disease

Allogene Therapeutics has reported preliminary safety, efficacy and translational data from the ongoing Phase I RESOLUTION study evaluating ALLO-329, an investigational, off-the-shelf allogeneic CAR-T product designed specifically for autoimmune disease.   The data were presented at the American College of Rheumatology (ACR) Convergence in Orlando, Florida. … Read More

#Editor's Choice #News

#Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Upcoming advances and challenges in cell & gene therapies webinar

Hosted by Drug Discovery World and supported by Bio-Techne this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More

#News

#Cell and gene therapy #Cell therapy #Drug discovery #Webinar

Webinar: Advances and challenges in cell & gene therapies

Hosted by Drug Discovery World and supported by Bio-Techne this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More

#News

CAR-T in multiple myeloma
#CAR-T #Caribou Biosciences #Cell therapy #Haematology #Oncology

Caribou Biosciences cancels allogeneic CAR-T programmes

Caribou Biosciences has announced that it is discontinuing its two allogeneic CAR-T cell therapy programmes due to financing constraints.  It will discontinue development of vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma. … Read More

#Cancer Research #News

#Cell and gene therapy #Cell therapy #Drug discovery #Gene therapy #Webinar

Have you registered for our CGT webinar?

Hosted by Drug Discovery World and supported by Bio-Techne this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More

#News

#Cell and gene therapy #Drug development #Drug discovery #Webinar

Webinar – Advances in cell and gene therapy

Hosted by Drug Discovery World and supported by Bio-Techne this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More

#News

CAR-T cells attack cancer cells
#CAR-T #Cell therapy #Generate Biomedicines #Oncology #Ovarian cancer

First human trials in ovarian cancer for ‘armoured’ CAR-T therapy

Roswell Park Comprehensive Cancer Center and Generate Biomedicines have dosed the first patient in a first-in-human clinical trial evaluating GB-5267, an autologous IL‑18–armoured CAR T-cell therapy.  The therapy is designed to overcome key barriers that have limited the success of cellular therapies in solid tumours.  … Read More

#Cancer Research #News #Trending News

Cell and gene therapy
#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy

Advances and challenges in cell and gene therapies

Hosted by Drug Discovery World and supported by Bio-Techne, this webinar explores the advances and challenges taking place within the cell and gene therapy field. Hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo Therapeutics. Throughout the… Read More

Webinar date:
Sponsored by Bio-Techne
#Featured Webinars

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Drug discovery #Webinar

Register now: Cell and gene therapy webinar

Hosted by Drug Discovery World and supported by Bio-Techne this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More

#News

#CNS #Gene therapy #Skylark Bio

Skylark Bio expands gene therapy pipeline into CNS

Skylark Bio has revealed it is expanding its pipeline with SKY-AS, a differentiated gene therapy candidate designed to restore UBE3A expression in individuals with Angelman syndrome (AS).   SKY-AS represents the company’s first central nervous system (CNS) development programme and expands Skylark’s portfolio of precision, locally delivered… Read More

#News

CAR-T cell therapy
#Bristol Myers Squibb #CAR-T #Cell therapy #Clinical trials #Novartis

Novartis and BMS pause CAR-T trials due to safety concerns

Novartis and Bristol Myers Squibb (BMS) have both paused clinical trials of CAR-T cell therapies for lupus and other autoimmune diseases due to concerning safety findings.  Novartis has placed holds on trials of rapcabtagene autoleucel (rap-cel), stopping screening, randomisation, and treatment administration in trials in lupus, myasthenia… Read More

#News #Trending News

CRISPR gene editing
#CRISPR-Cas9 #Dongguk University #Gene editing #Gene therapy

Discovery could make reversible gene therapy a reality

A new study has presented an innovative electromagnetic field (EMF)-responsive gene switch that enables fully reversible, safe, and precise control over gene expression.   “Gene switches” hold significant potential for understanding gene expression and for therapeutic applications, particularly for the non-invasive treatment or management of genetic disorders. … Read More

#News

Genetics researcher
#Gene therapy #Genespire #Genetic diseases #Paediatrics

Long-term study to inform gene therapy development

Genespire has commenced patient enrolment in an observational study, InforMMA, in children with methylmalonic acidemia (MMA) caused by mutations in the MMUT gene.  The study is designed to follow patients aged up to 16 years who live with severe MMA, with the aim of better characterising disease… Read More

#News